In the Claims:

This listing of claims will replace all prior versions and listing of claims in this application.

1. (currently amended) A compound of formula **(I):**



(I)

wherein

R^1 is ~~C_{1-10}~~ branched C_{3-5} alkyl, C_{3-8} alkenyl, C_{3-8} cycloalkyl, (C_{3-8} cycloalkyl)C_{1-6} alkyl, (C_{3-8} cycloalkyl)C_{3-8} alkenyl, or (C_{1-8} alkylcarbonyl)C_{1-8} alkyl;

n is 1;

X is O;

R^2 and R^3 independently are hydrogen, fluoro, chloro, bromo, nitro, trifluoromethyl, methyl, or C_{1-3}alkoxy;

R^4 is G

G is LQ;

L is $-CH_2-$;

Q is a saturated, un-substituted N-linked heterocyclyl, selected from the group consisting of azepanyl, morpholinyl, piperidinyl and pyrrolidinyl;

~~provided however that when R^1 is methyl, G is not piperidin-1-ylmethyl; and~~

wherein each of the above alkyl, alkenyl, and cycloalkyl, groups may each be independently and optionally substituted with between 1 and 3

substituents independently selected from trifluoromethyl, methoxy, halo, amino, nitro, hydroxy, and C_{1-3} alkyl;

~~provided that when R^1 is methyl, R^2 and R^3 are both H and X is O, then R^4 is not 4-morpholin-4-ylmethyl;~~

or a pharmaceutically acceptable salt, ester, tautomer or amide thereof.

2-3: Cancelled.

4. (original) A compound of claim 1, wherein wherein R^1 is isopropyl.

5-40: Cancelled

41. (original) A compound of claim 1 selected from the group consisting of:
(4-Azepan-1-ylmethyl-phenyl)-(4-*sec*-butyl-piperazin-1-yl)-methanone;
(4-Isopropyl-piperazin-1-yl)-(4-piperidin-1-ylmethyl-phenyl)-methanone;
(4-*sec*-Butyl-piperazin-1-yl)-(4-piperidin-1-ylmethyl-phenyl)-methanone;
{4-(1-Ethyl-propyl)-piperazin-1-yl}-(4-piperidin-1-ylmethyl-phenyl)-methanone;
{4-(1-Ethyl-propyl)-piperazin-1-yl}-(4-pyrrolidin-1-ylmethyl-phenyl)-methanone;
(4-Isopropyl-piperazin-1-yl)-(4-morpholin-4-ylmethyl-phenyl)-methanone;
(4-sec-Butyl-piperazin-1-yl)-(4-morpholin-4-ylmethyl-phenyl)-methanone dihydrochloride; and
{4-(1-Ethyl-propyl)-piperazin-1-yl}-(4-morpholin-4-ylmethyl-phenyl)-methanone dihydrochloride.

42. (original) A pharmaceutical composition, comprising a compound of claim 1 and a pharmaceutically-acceptable excipient.

43. (original) A compound of claim 1 isotopically-labelled to be detectable by PET or SPECT.

Claims 44-46: Cancelled

47. (withdrawn) A method for treating a disease or condition modulated by at least one receptor selected from the histamine H_1 receptor and the histamine H_3 receptor, said method comprising (a) administering to a subject a jointly effective amount of a histamine H_1 receptor antagonist compound, and (b) administering to the subject a jointly effective amount of a compound of claim 1, said method providing a jointly therapeutically effective amount of said compounds.

48. (withdrawn) The method of claim 47 wherein the histamine H_1 receptor antagonist and the compound of claim 1 are present in the same dosage form.

49. (withdrawn) A method for treating diseases or conditions modulated by at least one receptor selected from the histamine H_2 receptor and the histamine H_3 receptor in a subject, comprising (a) administering to the subject a jointly effective amount of a histamine H_2 receptor antagonist compound, and (b) administering to the subject a jointly effective amount of a compound of claim 1, said method providing a jointly therapeutically effective amount of said compounds.

50. (withdrawn) The method of claim 39 wherein the histamine H_2 receptor antagonist and the compound of claim 1 are present in the same dosage form.

51. (original) A method for treating one or more disorders or conditions selected from the group consisting of sleep/wake disorders, narcolepsy, and arousal/vigilance disorders, comprising administering to a subject a therapeutically effective amount of a compound of claim 1.

52. (original) A method for treating attention deficit hyperactivity disorders (ADHD), comprising administering to a subject a therapeutically effective amount of a compound of claim 1.

53. (original) A method for treating one or more disorders or conditions selected from the group consisting of dementia, mild cognitive impairment (pre-dementia), cognitive dysfunction, schizophrenia, depression, manic disorders, bipolar disorders, and learning and memory disorders, comprising administering to a subject a therapeutically effective amount of a compound of claim 1.

54-58: Cancelled

59. (previously presented) Acompound of claim 1, wherein R^1 is C_{3-8} cycloalkyl.

60. Cancelled.

61. (previously presented) A compound that is: (4-sec-Butyl-piperazin-1-yl)-(4-morpholin-4-ylmethyl-phenyl)-methanone dihydrochloride.

62. (previously presented) A compound that is: {4-(1-Ethyl-propyl)-piperazin-1-yl}-(4-morpholin-4-ylmethyl-phenyl)-methanone dihydrochloride.

63. (previously presented) A compound that is: {4-(1-Ethyl-propyl)-piperazin-1-yl}-{4-(decahydro-isoquinolin-2-ylmethyl)-phenyl}-methanone.

64. (new) A compound of formula **(I):**



(I)

wherein

R^1 is C_{3-8} cycloalkyl;

n is 1;

X is O;

R^2 and R^3 independently are hydrogen, fluoro, chloro, bromo, nitro, trifluoromethyl, methyl, or C_{1-3}alkoxy;

R^4 is G

G is LQ;

L is $-CH_2-$;

Q is azepanyl, morpholinyl, piperidinyl or pyrrolidinyl; and

wherein each of the above cycloalkyl groups may each be independently and optionally substituted with between 1 and 3 substituents independently selected from trifluoromethyl, methoxy, halo, amino, nitro, hydroxyl, and C_{1-3} alkyl;

or a pharmaceutically acceptable salt, ester, tautomer or amide thereof.

65. (new) A compound of claim 64, wherein Q is morpholinyl.

66. (new) A pharmaceutical composition, comprising a compound of claim 64 and a pharmaceutically-acceptable excipient.

67. (new) A compound of claim 64 isotopically-labelled to be detectable by PET or SPECT.

68. (new) A method for treating one or more disorders or conditions selected from the group consisting of sleep/wake disorders, narcolepsy, and arousal/vigilance disorders, comprising administering to a subject a therapeutically effective amount of a compound of claim 64.

69. (new) A method for treating attention deficit hyperactivity disorders (ADHD), comprising administering to a subject a therapeutically effective amount of a compound of claim 64.

70. (new) A method for treating one or more disorders or conditions selected from the group consisting of dementia, mild cognitive impairment (pre-dementia), cognitive dysfunction, schizophrenia, depression, manic disorders, bipolar disorders, and learning and memory disorders, comprising administering to a subject a therapeutically effective amount of a compound of claim 64.

71. (new) A compound of formula **(I):**



(I)

wherein

R^1 is branched C_{3-5} alkyl;

n is 1;

X is O;

R^2 and R^3 independently are hydrogen, fluoro, chloro, bromo, nitro, trifluoromethyl, methyl, or C_{1-3}alkoxy;

R^4 is G

G is LQ;

L is $–CH_2-$;

Q is azepanyl, morpholinyl, piperidinyl or pyrrolidinyl; and

wherein each of the above alkyl groups may each be independently and optionally substituted with between 1 and 3 substituents independently selected from trifluoromethyl, methoxy, halo, amino, nitro, hydroxyl, and C_{1-3} alkyl;

or a pharmaceutically acceptable salt, ester, tautomer or amide thereof.

72. (new) A compound of claim 71, wherein R^1 is isopropyl.

73. (new) A compound of claim 71, wherein Q is morpholinyl.

74. (new) A compound of claim 71, wherein R^1 is isopropyl, R^2 is hydrogen, R^3 is hydrogen and Q is morpholinyl.

75. (new) A compound that is: (4-Isopropyl-piperazin-1-yl)-(4-morpholin-4-ylmethyl-phenyl)-methanone.

76. (new) A pharmaceutical composition, comprising a compound of claim 71 and a pharmaceutically-acceptable excipient.

77. (new) A compound of claim 71 isotopically-labelled to be detectable by PET or SPECT.

78. (new) A method for treating one or more disorders or conditions selected from the group consisting of sleep/wake disorders, narcolepsy, and arousal/vigilance disorders, comprising administering to a subject a therapeutically effective amount of a compound of claim 71.

79. (new) A method for treating attention deficit hyperactivity disorders (ADHD), comprising administering to a subject a therapeutically effective amount of a compound of claim 71.

80. (new) A method for treating one or more disorders or conditions selected from the group consisting of dementia, mild cognitive impairment (pre-dementia), cognitive dysfunction, schizophrenia, depression, manic disorders, bipolar disorders, and learning and memory disorders, comprising administering to a subject a therapeutically effective amount of a compound of claim 71.